Aizen Therapeutics Partners with San Diego Biopharma for Oral Biologics Development

Aizen Therapeutics, an AI-native biotechnology company, has announced a multi-program collaboration with a San Diego-based public biopharmaceutical company focused on developing oral biologics. The agreement has a potential revenue stream of up to $100 million per target program.

The collaboration aims to leverage Aizen's artificial intelligence platform to create biologic drugs that can be administered orally. This approach seeks to overcome the limitations of current biologic therapies, which typically require injections and can be less convenient for patients.

The partnership is expected to accelerate the development of novel therapeutic options for various diseases. By focusing on oral administration, the companies aim to improve patient access and adherence to treatment.

Further details regarding the specific therapeutic areas and the timeline for development have not yet been disclosed. Both companies will concentrate on the initial phases of the collaborative programs.